Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Raised by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,956,583 shares of the biotechnology company's stock after buying an additional 10,343 shares during the period. T. Rowe Price Investment Management Inc. owned 2.05% of Sarepta Therapeutics worth $237,901,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after buying an additional 117,904 shares during the last quarter. Capital International Investors boosted its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the period. Geode Capital Management LLC boosted its position in Sarepta Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock valued at $207,538,000 after buying an additional 9,999 shares during the period. Norges Bank acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at $126,315,000. Finally, Erste Asset Management GmbH raised its holdings in shares of Sarepta Therapeutics by 11.3% in the 4th quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock valued at $86,116,000 after purchasing an additional 72,183 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $0.55 during mid-day trading on Tuesday, reaching $62.06. The company had a trading volume of 272,680 shares, compared to its average volume of 1,419,497. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $6.02 billion, a P/E ratio of 49.63 and a beta of 0.93. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25. The stock's 50-day simple moving average is $76.41 and its two-hundred day simple moving average is $105.15.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They set an "overweight" rating and a $115.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price target for the stock from $161.00 to $87.00 in a research note on Monday, March 31st. HC Wainwright restated a "neutral" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, April 16th. Finally, Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.